| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17405 R72982 |
Madley-Dowd_SE (Carbamazepine) (Controls exposed to LTG) (Mixed indications), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes Partial overlapping |
1.46 [1.14;1.86] excluded (control group) |
136/2,427 134/5,035 | 270 | 2,427 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17406 R72986 |
Madley-Dowd_SE (Carbamazepine) (Controls unexposed, general pop) (Mixed indications), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 1.21 [1.01;1.45] | 136/2,427 68,788/2,651,210 | 68,924 | 2,427 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17407 R72990 |
Madley-Dowd_SE (Carbamazepine) (Controls unexposed, sibling) (Mixed indications), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | sibling excluded | Adjustment: Yes Partial overlapping |
1.13 [0.68;1.90] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17280 R72325 |
Madley-Dowd_UK (Carbamazepine) (Controls exposed to LTG) (Mixed indications), 2024 | Autism - ICD10 codes - Median CBZ 9.17 (5.31-12.54) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
1.41 [0.73;2.71] excluded (control group) |
21/603 20/939 | 41 | 603 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17264 R72273 |
Madley-Dowd_UK (Carbamazepine) (Controls unexposed, general pop) (Mixed indications), 2024 | Autism - ICD10 codes - Median CBZ 9.17 (5.31-12.54) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.55 [0.94;2.53] | 21/603 7,657/514,066 | 7,678 | 603 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17272 R72300 |
Madley-Dowd_UK (Carbamazepine) (Controls unexposed, sibling) (Mixed indications), 2024 | Autism - ICD10 codes - Median CBZ 9.17 (5.31-12.54) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | sibling excluded | Adjustment: Yes |
1.79 [0.66;4.79] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12749 R48103 |
Bjørk (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) - Median follow up carbamazepine 10.5 (6.4-16.6) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.22 [0.84;1.78] C excluded (control group) |
41/3,256 82/7,950 | 123 | 3,256 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12748 R48100 |
Bjørk (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) - Median follow up carbamazepine 10.5 (6.4-16.6) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
1.36 [1.00;1.85] excluded (control group) |
41/3,256 38,437/4,463,879 | 38,478 | 3,256 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12747 R48097 |
Bjørk (Carbamazepine) (Controls unexposed, sick) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) - Median follow up carbamazepine 10.5 (6.4-16.6) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 1.02 [0.73;1.42] C | 41/3,256 267/21,634 | 308 | 3,256 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9776 R34963 |
Coste (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
1.30 [0.30;5.00] excluded (control group) |
3/502 11/2,916 | 14 | 502 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9777 R34981 |
Coste (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.70 [0.50;5.20] | 3/468 4,254/1,707,707 | 4,257 | 468 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9723 R34604 |
Huber-Mollema (Carbamazepine), 2019 | Diagnosis of autism spectrum disorder | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.20 [0.21;6.85] C | 2/37 4/88 | 6 | 37 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9750 R34812 |
Wood (Carbamazepine), 2015 | Score >30 (CARS) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.78 [0.03;21.03] C | 1/34 0/9 | 1 | 34 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9696 R35905 |
Bromley (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 | Autistic Spectrum Disorders (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.19 [0.01;4.87] C excluded (control group) |
0/50 1/30 | 1 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9699 R35906 |
Bromley (Carbamazepine) (Controls unexposed, disease free), 2013 | Autistic Spectrum Disorders (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
0.47 [0.02;8.88] C excluded (control group) |
0/50 4/214 | 4 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9702 R35907 |
Bromley (Carbamazepine) (Controls unexposed, sick), 2013 | Autistic Spectrum Disorders (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.52 [0.01;26.73] C | 0/50 0/26 | 0 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 7 studies | 1.20 [1.03;1.39] | 81,174 | 6,875 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine) (Controls unexposed, general pop) (Mixed indications; 2: Carbamazepine) (Controls unexposed, general pop) (Mixed indications; 3: Carbamazepine) (Controls unexposed, sick) (Mixed indications; 4: Carbamazepine) (Controls unexposed, NOS) (Mixed indications; 5: Carbamazepine; 6: Carbamazepine; 7: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.9628 (by Egger's regression)
slope=0.1792 (0.0766); intercept=0.0187 (0.3807); t=0.0490; p=0.9628
excluded 9696, 9699, 9776, 12749, 12748, 17405, 17407, 17280, 17272